Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 86967-55-7 | MDL No. : | MFCD11506159 |
Formula : | C6H12ClNO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | LFOMNFLGCFFCQJ-UHFFFAOYSA-N |
M.W : | 181.62 | Pubchem ID : | 13099576 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.83 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 45.38 |
TPSA : | 58.56 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -9.18 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | -2.49 |
Log Po/w (WLOGP) : | -0.13 |
Log Po/w (MLOGP) : | -0.5 |
Log Po/w (SILICOS-IT) : | 0.21 |
Consensus Log Po/w : | -0.58 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | 0.73 |
Solubility : | 986.0 mg/ml ; 5.43 mol/l |
Class : | Highly soluble |
Log S (Ali) : | 1.8 |
Solubility : | 11500.0 mg/ml ; 63.5 mol/l |
Class : | Highly soluble |
Log S (SILICOS-IT) : | -0.31 |
Solubility : | 89.6 mg/ml ; 0.493 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.39 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
42% | With potassium carbonate; In ethanethiol; at 25.0℃; for 16.0h; | A mixture of ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (7.7 g, 15.3 mmol), (S)-morpholine-3-carboxylic acid (2 g, 15.3 mmol) and potassium carbonate (4.23 g, 30.6 mmol) in anhydrous ethanol (154 mL) was stirred at 25 C. for 16 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH (V/V)=25/1) to give the title compound as a yellow solid (7.26 g, 86%). The compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.ion) m/z: 553.2 [M+1]+; 1H NMR (400 MHz, DMSO-d6): delta 12.90 (s, 1H), 9.84 (s, 1H), 8.04 (d, 1H), 7.95 (d, 1H), 7.57-7.55 (m, 1H), 7.43-7.37 (m, 1H), 7.23-7.19 (m, 1H), 6.03 (s, 1H), 4.30-3.92 (m, 5H), 3.84-3.82 (m, 1H), 3.74-3.52 (m, 3H), 3.11-3.07 (m, 1H), 2.55-2.39 (m, 1H), 1.06 (t, 3H).Ethyl 6-(bromomethyl)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (0.82 g, 1.53 mmol) (The compound was synthesized according to the procedure as described in U.S. Pat. No. 7,074,784) was reacted with <strong>[86967-55-7]2-(morpholin-3-yl)acetic acid hydrochloride</strong> (0.28 g, 1.53 mmol) according to the procedure as described in Example 28 to give the title compound as a yellow solid (0.38 g, 42%). The compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.ion) m/z: 597.1 [M+1]+; 1H NMR (400 MHz, DMSO-d6): delta 9.75 (s, 1H), 8.55 (d, 1H), 8.05-7.95 (m, 1H), 7.58-7.55 (m, 1H), 7.44-7.38 (m, 1H), 7.24-7.18 (m, 1H), 4.19-3.90 (m, 4H), 3.77-3.53 (m, 4H), 3.11-2.69 (m, 3H), 2.51-2.41 (m, 2H), 1.07 (t, 3H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
86% | With potassium carbonate; In ethanol; at 25.0℃; for 16.0h; | General procedure: A mixture of ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (7.7 g, 15.3 mmol), (S)-morpholine-3-carboxylic acid (2 g, 15.3 mmol) and potassium carbonate (4.23 g, 30.6 mmol) in anhydrous ethanol (154 mL) was stirred at 25 C. for 16 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH (V/V)=25/1) to give the title compound as a yellow solid (7.26 g, 86%). The compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.ion) m/z: 553.2 [M+1]+; 1H NMR (400 MHz, DMSO-d6): delta 12.90 (s, 1H), 9.84 (s, 1H), 8.04 (d, 1H), 7.95 (d, 1H), 7.57-7.55 (m, 1H), 7.43-7.37 (m, 1H), 7.23-7.19 (m, 1H), 6.03 (s, 1H), 4.30-3.92 (m, 5H), 3.84-3.82 (m, 1H), 3.74-3.52 (m, 3H), 3.11-3.07 (m, 1H), 2.55-2.39 (m, 1H), 1.06 (t, 3H). Ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (0.76 g, 1.53 mmol) (The compound was synthesized according to the procedure as described in WO2010069147) was reacted with <strong>[86967-55-7]2-(morpholin-3-yl)acetic acid hydrochloride</strong> (0.28 g, 1.53 mmol) according to the procedure as described in Example 28 to give the title compound as a yellow solid (0.42 g, 49%). The compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.ion) m/z: 560.1 [M+1]+; 1H NMR (400 MHz, DMSO-d6): delta 12.31 (s, 1H), 10.17 (s, 1H), 7.85-7.67 (m, 2H), 7.56-7.44 (m, 3H), 7.38-7.28 (m, 1H), 7.31-7.26 (m, 1H), 7.10-6.99 (m, 1H), 6.25 (s, 1H), 4.21-3.94 (m, 3H), 3.76-3.43 (m, 2H), 3.27-3.06 (m, 1H), 3.00-2.95 (m, 2H), 2.72-2.65 (m, 1H), 2.62-2.58 (m, 2H), 2.52-2.47 (m, 1H), 2.33-2.11 (m, 1H), 1.08 (t, 3H). |
[ 1807882-36-5 ]
trans-2-Methylmorpholine-3-carboxylic acid hydrochloride
Similarity: 0.75
[ 1352709-57-9 ]
(S)-2-(Morpholin-2-yl)acetic acid hydrochloride
Similarity: 0.71
[ 439918-59-9 ]
(R)-2-(Pyrrolidin-2-yl)acetic acid hydrochloride
Similarity: 0.71
[ 1799443-47-2 ]
(S)-Methyl 2-(morpholin-3-yl)acetate hydrochloride
Similarity: 0.95
[ 1807882-36-5 ]
trans-2-Methylmorpholine-3-carboxylic acid hydrochloride
Similarity: 0.75
[ 259868-83-2 ]
(S)-Methyl 2-(pyrrolidin-2-yl)acetate hydrochloride
Similarity: 0.74
[ 340040-67-7 ]
(R)-Methyl 2-(pyrrolidin-2-yl)acetate hydrochloride
Similarity: 0.74
[ 1799443-47-2 ]
(S)-Methyl 2-(morpholin-3-yl)acetate hydrochloride
Similarity: 0.95
[ 218594-88-8 ]
(S)-3-Ethylmorpholine hydrochloride
Similarity: 0.76
[ 1807882-36-5 ]
trans-2-Methylmorpholine-3-carboxylic acid hydrochloride
Similarity: 0.75